Miranda L Hanson1, Julie A Hixon1, Wenqing Li1, Barbara K Felber2, Miriam R Anver3, C Andrew Stewart1, Brian M Janelsins4, Sandip K Datta4, Wei Shen1, Mairi H McLean1, Scott K Durum5. 1. Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland. 2. Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, Maryland. 3. Laboratory Animal Services Program, Science Applications International Corporation, National Cancer Institute, Frederick, Maryland. 4. Bacterial Pathogenesis Unit, Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. 5. Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland. Electronic address: durums@mail.nih.gov.
Abstract
BACKGROUND & AIMS: Treatment of inflammatory bowel disease would benefit from specific targeting of therapeutics to the intestine. We developed a strategy for localized delivery of the immunosuppressive cytokine interleukin (IL)-27, which is synthesized actively in situ by the food-grade bacterium Lactococcus lactis (LL-IL-27), and tested its ability to reduce colitis in mice. METHODS: The 2 genes encoding mouse IL-27 were synthesized with optimal codon use for L lactis and joined with a linker; a signal sequence was added to allow for product secretion. The construct was introduced into L lactis. Colitis was induced via transfer of CD4(+)CD45RB(hi) T cells into Rag(-/-) mice to induce colitis; 7.5 weeks later, LL-IL-27 was administered to mice via gavage. Intestinal tissues were collected and analyzed. RESULTS: LL-IL-27 administration protected mice from T-cell transfer-induced enterocolitis and death. LL-IL-27 reduced disease activity scores, pathology features of large and small bowel, and levels of inflammatory cytokines in colonic tissue. LL-IL-27 also reduced the numbers of CD4(+) and IL-17(+) T cells in gut-associated lymphoid tissue. The effects of LL-IL-27 required production of IL-10 by the transferred T cells. LL-IL-27 was more effective than either LL-IL-10 or systemic administration of recombinant IL-27 in reducing colitis in mice. LL-IL-27 also reduced colitis in mice after administration of dextran sodium sulfate. CONCLUSIONS: LL-IL-27 reduces colitis in mice by increasing the production of IL-10. Mucosal delivery of LL-IL-27 could be a more effective and safer therapy for inflammatory bowel disease. Published by Elsevier Inc.
BACKGROUND & AIMS: Treatment of inflammatory bowel disease would benefit from specific targeting of therapeutics to the intestine. We developed a strategy for localized delivery of the immunosuppressive cytokine interleukin (IL)-27, which is synthesized actively in situ by the food-grade bacterium Lactococcus lactis (LL-IL-27), and tested its ability to reduce colitis in mice. METHODS: The 2 genes encoding mouseIL-27 were synthesized with optimal codon use for L lactis and joined with a linker; a signal sequence was added to allow for product secretion. The construct was introduced into L lactis. Colitis was induced via transfer of CD4(+)CD45RB(hi) T cells into Rag(-/-) mice to induce colitis; 7.5 weeks later, LL-IL-27 was administered to mice via gavage. Intestinal tissues were collected and analyzed. RESULTS:LL-IL-27 administration protected mice from T-cell transfer-induced enterocolitis and death. LL-IL-27 reduced disease activity scores, pathology features of large and small bowel, and levels of inflammatory cytokines in colonic tissue. LL-IL-27 also reduced the numbers of CD4(+) and IL-17(+) T cells in gut-associated lymphoid tissue. The effects of LL-IL-27 required production of IL-10 by the transferred T cells. LL-IL-27 was more effective than either LL-IL-10 or systemic administration of recombinant IL-27 in reducing colitis in mice. LL-IL-27 also reduced colitis in mice after administration of dextran sodium sulfate. CONCLUSIONS:LL-IL-27 reduces colitis in mice by increasing the production of IL-10. Mucosal delivery of LL-IL-27 could be a more effective and safer therapy for inflammatory bowel disease. Published by Elsevier Inc.
Authors: Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho Journal: Science Date: 2006-10-26 Impact factor: 47.728
Authors: Masahito Kamanaka; Sean T Kim; Yisong Y Wan; Fayyaz S Sutterwala; Maria Lara-Tejero; Jorge E Galán; Ed Harhaj; Richard A Flavell Journal: Immunity Date: 2006-11-30 Impact factor: 31.745
Authors: Jason S Stumhofer; Jonathan S Silver; Arian Laurence; Paige M Porrett; Tajie H Harris; Laurence A Turka; Matthias Ernst; Christiaan J M Saris; John J O'Shea; Christopher A Hunter Journal: Nat Immunol Date: 2007-11-11 Impact factor: 25.606
Authors: Amit Awasthi; Yijun Carrier; Jean P S Peron; Estelle Bettelli; Masahito Kamanaka; Richard A Flavell; Vijay K Kuchroo; Mohamed Oukka; Howard L Weiner Journal: Nat Immunol Date: 2007-11-11 Impact factor: 25.606
Authors: Alejandro V Villarino; David Artis; Jelena S Bezbradica; Omer Miller; Christiaan J M Saris; Sebastian Joyce; Christopher A Hunter Journal: Int Immunol Date: 2008-03-28 Impact factor: 4.823
Authors: Ross John Porter; Caroline Andrews; Daniel Paul Brice; Scott Kenneth Durum; Mairi Hall McLean Journal: Inflamm Bowel Dis Date: 2018-09-15 Impact factor: 5.325
Authors: Rakeshchandra R Meka; Shivaprasad H Venkatesha; Steven Dudics; Bodhraj Acharya; Kamal D Moudgil Journal: Autoimmun Rev Date: 2015-08-05 Impact factor: 9.754